Related references
Note: Only part of the references are listed.Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer
Patrick N. Song et al.
CANCERS (2022)
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
Ilaria Marrocco et al.
EMBO MOLECULAR MEDICINE (2021)
Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment
Jagmohan Singh et al.
VACCINES (2021)
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
Stephen C. Frederico et al.
FRONTIERS IN ONCOLOGY (2021)
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
Naomi Dempsey et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures
Christel Larbouret et al.
CANCERS (2021)
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Mary Luz Uribe et al.
CANCERS (2021)
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
Maria Gaibar et al.
JOURNAL OF ONCOLOGY (2020)
Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity
Yaima Tundidor et al.
SCIENTIFIC REPORTS (2020)
Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs
Chun-wei Xu et al.
TRANSLATIONAL ONCOLOGY (2020)
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
Donatella Romaniello et al.
CANCERS (2020)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
Donatella Romaniello et al.
CLINICAL CANCER RESEARCH (2018)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside
Yanelys Morera-Diaz et al.
SEMINARS IN ONCOLOGY (2018)
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors
Maicol Mancini et al.
EMBO MOLECULAR MEDICINE (2018)
Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies
Narjara Gonzalez Suarez et al.
ONCOTARGET (2017)
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Margaret E. Gatti-Mays et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial
Iraida Caballero et al.
FRONTIERS IN PHARMACOLOGY (2017)
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
Zaima Mazorra et al.
FRONTIERS IN PHARMACOLOGY (2017)
The use of combinations of monoclonal antibodies in clinical oncology
Linda M. Henricks et al.
CANCER TREATMENT REVIEWS (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the THERAPY phase 1-2 trial
Eric Assenat et al.
ONCOTARGET (2015)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells
Audry Fernandez et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
Hui K. Gan et al.
FEBS JOURNAL (2013)
A view on EGFR-targeted therapies from the oncogene-addiction perspective
Rolando Perez et al.
FRONTIERS IN PHARMACOLOGY (2013)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt et al.
NATURE REVIEWS CANCER (2013)
Targeting the EGFR signaling pathway in cancer therapy
Parthasarathy Seshacharyulu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions
Liliana Oliver et al.
VACCINE (2012)
Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study
Ana M. Bada Barro et al.
VACCINE (2012)
Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family
Ying-Nai Wang et al.
CELL AND BIOSCIENCE (2012)
Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
Timothy Kute et al.
ONCOIMMUNOLOGY (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Bivalent binding by intermediate affinity of nimotuzumab A contribution to explain antibody clinical profile
Greta Garrido et al.
CANCER BIOLOGY & THERAPY (2011)
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
Klaus Koefoed et al.
MABS (2011)
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
C. Larbouret et al.
ANNALS OF ONCOLOGY (2010)
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
D. D. Meira et al.
BRITISH JOURNAL OF CANCER (2009)
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
Tsipi Ben-Kasus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
Z. Tang et al.
BRITISH JOURNAL OF CANCER (2008)
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425
Vishal Kamat et al.
CANCER BIOLOGY & THERAPY (2008)
Mechanisms of resistance to ErbB-targeted cancer therapeutics
Qiang Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling
K. Shtiegman et al.
ONCOGENE (2007)
Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant
Belinda Sanchez Ramirez et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
LM Friedman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Very small size proteoliposomes derived from Neisseria meningitidis:: an effective adjuvant for Th1 induction and dendritic cell activation
C Mesa et al.
VACCINE (2004)
Epidermal growth factor receptor tyrosine kinase inhibitors
M Ranson
BRITISH JOURNAL OF CANCER (2004)
Cancer vaccines: Between the idea and the reality
OJ Finn
NATURE REVIEWS IMMUNOLOGY (2003)
Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment
DH Lynch et al.
SEMINARS IN ONCOLOGY (2002)
Share Paper
